China’s 2025 Labor Day Sees Surge in Inbound and Outbound Travel Spending via Alipay and Other Alipay+ Partner Payment Apps
Data from Alipay and other Alipay+ partner payment apps indicates a notable increase in both outbound and inbound tourism spending in China during the 2025 Labor Day holiday (Golden Week).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505144383/en/
The Myeongdong shopping area in South Korea welcomes travelers to pay with Alipay and other Alipay+ partner payment apps.
Outbound Travel: Chinese tourists explore local experiences through digital platforms in overseas destinations
Through Alipay+, a unified wallet gateway with cross-border payment and digitization services developed by Ant International, users of 36 e-wallets in Asia and Europe—including Chinese travelers—can use their own home payment apps across over 70 markets without the need to exchange currency or carry cash. During China's Labor Day holiday, global Alipay+ merchants have joined Alipay in an exclusive campaign to lure travelers.
The top destinations for Chinese travelers, based on total Alipay spending, are Hong Kong SAR, Japan, Macao SAR, South Korea, Thailand, Malaysia, Singapore, France, Canada, and Italy.
Thanks to Alipay+'s 100 million-strong and diverse global merchant network, Chinese tourists are increasingly seeking more personalized, local experiences. Switzerland recorded the highest average Alipay spending per user, while in South Korea, average spending exceeded USD 100—driven in part by the growing trend of traveling for cosmetic surgery. In addition, the growing desire for immersive local travel experiences is driving increased use of local transportation, with Alipay transactions rising 53% year-over-year. Public transit has become the most frequently used Alipay service among travelers. Taking buses and subways with Alipay is especially popular in Hong Kong SAR and Macao SAR, where travelers are already familiar with using it for daily commutes. Other emerging trends include buying train tickets in Europe and unlocking shared bikes in Japan with Alipay.
Furthermore, Alipay’s real-time tax refund service saw a 33% year-on-year increase in the refund value per transaction, while the number of claims for Alipay’s instant discount offer increased by 46% compared to the New Year’s Day holiday.
Inbound Travel: Visa-free entry, updated tax refund policies, and new payment options attract international travelers
Since September 2023, the Alipay+ solutions have supported 13 leading payment apps1 in Asia to serve their roaming users across Alipay’s extensive merchant network in China.
Thanks to China’s updated tax refund and visa-free policies, more international travelers are heading to the country. During the Labor Day holiday, both the number of transactions and the total spending by travelers using the 13 overseas e-wallets rose by over 100% year-on-year.AlipayHK topped the list for total spending, followed by Malaysia’s Touch ’n Go e-Wallet, Kazakhstan’s Kaspi.kz, Macao SAR’s MPay, and Thailand’s TrueMoney.
With Alipay+, international travelers may also bind their Visa, Mastercard, American Express, JCB, Discover®, Diners Club International®, and UnionPay International credit or debit cards to Alipay for a seamless travel experience in China. This enables smooth payments and access to a wide range of digital services on the Alipay platform, including ride-hailing, hotel bookings, and plane or train ticket purchases.
Alipay Tap!—a contactless payment and customer engagement solution introduced by Alipay in China in June 2024—has also quickly become a preferred payment method among international travelers to China. The solution is essentially a simplified QR-code method that enables users to access services hosted on Alipay simply by tapping a merchant’s terminal or an Alipay Tap! Tag, without needing to open an app, scan a code, or navigate multiple screens. As of April 2025, Alipay Tap! had attracted over 100 million users in China within just 11 months of launch. During the Labor Day holiday, travelers from the 54 countries covered by China’s 240-hour visa-free transit policy spent 50% more via Alipay Tap! compared to the same period in April.
About Alipay+
Ant International's Alipay+ is a unified wallet gateway with cross-border payment and digitization services that help connect global merchants to consumers. Consumers enjoy seamless payments a broad choice of deals and the convenience of digital services using their preferred payment app/e-wallet while travelling abroad. Many small and medium-sized businesses already use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.
About Alipay
As the world becomes increasingly digital, Alipay has evolved from a trusted e-wallet into an all-in-one digital platform for daily services, connecting more than one billion consumers to over 80 million merchants across China. Alipay offers users a secure, seamless mobile payment experience and integrates over 10,000 services across sectors like travel, healthcare, tourism, and entertainment. With digital tools like Alipay Tap!, mini-programs, lifestyle accounts, Alipay enables merchants, institutions, and independent software vendors (ISVs) to enhance operational efficiency and effectiveness. In addition, Alipay is developing a new AI-driven open platform by integrating AI agents to deliver smarter, more personalized services to its users as well as facilitating the digital transformation of the service sector.
____________________ 1 The 13 payment apps include AlipayHK (Hong Kong SAR, China), Kaspi.kz (Kazakhstan), MPay (Macao SAR, China), Touch ’n Go eWallet (Malaysia), Hipay (Mongolia), NayaPay (Pakistan), Changi Pay (Singapore), OCBC Digital (Singapore), Kakao Pay (South Korea), Naver Pay (South Korea), Toss Pay (South Korea), TrueMoney (Thailand), GCash (The Philippines). |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250505144383/en/
Contacts
Media Inquiries
Yinan Duan
globalcomms@antgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom